SEC Form 4 · accession 0001140361-18-029033
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Henry J Fuchs
Officer — President, Worldwide R&D
Period of report
Jun 14, 2018
Accepted (ET)
Jun 18, 2018 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 14, 2018 | M | 2,000 | $21.51 | A | 157,167 | D | |
| Common StockF1 | Jun 14, 2018 | S | 2,000 | $90.00 | D | 155,167 | D | |
| Common StockF1 | Jun 14, 2018 | M | 3,775 | $26.49 | A | 158,942 | D | |
| Common StockF1 | Jun 14, 2018 | S | 3,775 | $90.00 | D | 155,167 | D | |
| Common StockF1 | Jun 14, 2018 | M | 2,669 | $37.46 | A | 157,836 | D | |
| Common StockF1 | Jun 14, 2018 | S | 2,669 | $90.00 | D | 155,167 | D | |
| Common StockF1 | Jun 14, 2018 | M | 1,875 | $26.49 | A | 157,042 | D | |
| Common StockF1 | Jun 14, 2018 | S | 1,875 | $90.00 | D | 155,167 | D | |
| Common StockF1 | Jun 14, 2018 | M | 20,681 | $37.46 | A | 175,848 | D | |
| Common StockF1,F2 | Jun 14, 2018 | S | 20,681 | $90.0041 | D | 155,167 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F3 | $21.51 | Jun 14, 2018 | M | 2,000 | D | Nov 12, 2010 | May 11, 2020 | Common Stock | 2,000 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $26.49 | Jun 14, 2018 | M | 3,775 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 3,775 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $37.46 | Jun 14, 2018 | M | 2,669 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 2,669 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $26.49 | Jun 14, 2018 | M | 1,875 | D | Nov 12, 2011 | May 11, 2021 | Common Stock | 1,875 | 0 | D |
| Stock Option (Right to buy Common Stock)F1,F3 | $37.46 | Jun 14, 2018 | M | 20,681 | D | Nov 8, 2012 | May 7, 2022 | Common Stock | 20,681 | 0 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on May 30, 2018.
- F2The price in column 4 is the weighted average price. The price actually received ranged from $90.00 to $90.07. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- F3Reflects the number of options outstanding after the transactions from this specific stock option grant.